Aeolus Announces No-Cost Extension and Modification of Barda Contract Fully Valued at $118 Million to Develop Treatment for Lung Acute Radiation Syndrome
February 15, 2012 10:35 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Feb 15, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS)
Restructure driven by additional items added to base...
Aeolus Pharmaceuticals Announces First Quarter Fiscal Year 2012 Financial Results
February 13, 2012 17:40 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Feb 13, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS)
$2.2 million in revenue
Meeting to request...
Aeolus' AEOL 10150 Protects Lung Tissue From Radiation by Modulating PTEN Levels, Reducing Oxidative Stress and Apoptosis
February 08, 2012 14:35 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Feb 8, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS)
Data published in the International Journal of Radiation...
Positive Data on AEOL 11207 in Pre-Clinical Epilepsy Model Published in the Journal of Neurobiology of Disease
February 07, 2012 06:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Feb 7, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company leveraging significant government funding to develop a...
Aeolus to Present at the Noble Financial Capital Markets' 8th Annual Equity Conference
January 17, 2012 06:58 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Jan 17, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company leveraging significant government funding to develop a...
Aeolus Pharmaceuticals Announces Fiscal Year 2011 Results
December 27, 2011 19:10 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Dec 27, 2011) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company leveraging significant government funding to develop a...
Aeolus to Present at the 22nd Annual Oppenheimer Healthcare Conference
December 07, 2011 11:17 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Dec 7, 2011) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company leveraging significant government funding to develop a...
Aeolus to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
November 09, 2011 09:05 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Nov 9, 2011) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company leveraging significant government funding to develop a platform...
Aeolus Pharmaceuticals Announces Positive Results From Study of AEOL 10150 and Neupogen(R) as Combination Therapy for Treatment of Acute Radiation Syndrome
November 01, 2011 08:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Nov 1, 2011) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company leveraging significant government funding to develop a...
Aeolus to Present at the 10th Annual BIO Investor Forum
October 24, 2011 10:02 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Oct 24, 2011) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company leveraging significant funding from the U.S. Department of...